Y-Mabs Therapeutics Inc’s filing revealed that its CHIEF BUSINESS OFFICER Gad Thomas unloaded Company’s shares for reported $64116.0 on Mar 05 ’24. In the deal valued at $16.44 per share,3,900 shares were sold. As a result of this transaction, Gad Thomas now holds 158,700 shares worth roughly $2.4 million.
Then, Rajah Vignesh sold 1,711 shares, generating $28,283 in total proceeds. Upon selling the shares at $16.53, the SVP & CHIEF MEDICAL OFFICER now owns 33,889 shares.
Before that, Smith Susan Laura sold 1,682 shares. Y-Mabs Therapeutics Inc shares valued at $27,837 were divested by the SVP & CHIEF COMMERCIAL OFFICER at a price of $16.55 per share. As a result of the transaction, Smith Susan Laura now holds 33,918 shares, worth roughly $0.51 million.
Wedbush upgraded its Y-Mabs Therapeutics Inc [YMAB] rating to an Outperform from a a Neutral in a research note published on May 10, 2023; the price target was increased to $13 from $5. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early April from “a Buy” to “a Neutral”. Morgan Stanley also remained covering YMAB and has decreased its forecast on January 27, 2023 with a “an Underweight” recommendation from previously “an Equal-weight” rating. Cowen revised its rating on January 05, 2023. It rated YMAB as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of YMAB
On Tuesday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock jump 1.54% to $15.14. Over the last five days, the stock has gained 7.60%. Y-Mabs Therapeutics Inc shares have risen nearly 121.99% since the year began. Nevertheless, the stocks have risen 131.50% over the past one year. While a 52-week high of $20.90 was reached on 03/01/24, a 52-week low of $4.60 was recorded on 01/03/24. SMA at 50 days reached $15.54, while 200 days put it at $8.68. A total of 0.44 million shares were traded, compared to the trading of 0.24 million shares in the previous session.
Levels Of Support And Resistance For YMAB Stock
The 24-hour chart illustrates a support level at 14.53, which if violated will result in even more drops to 13.91. On the upside, there is a resistance level at 15.72. A further resistance level may holdings at 16.30. The Relative Strength Index (RSI) on the 14-day chart is 50.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.63%. Stochastics %K at 35.34% indicates the stock is a holding.
